Administration Of Calcium Gluconate for The Reduction of Blood Loss During Vaginal Delivery

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Postpartum Hemorrhage

In brief

Postpartum hemorrhage is one of the leading causes of maternal morbidity following childbirth. Even when excessive bleeding is not clinically recognized, some women experience a significant decrease in hemoglobin levels after delivery, which may result in anemia, fatigue, delayed recovery, and the need for additional medical treatment. Calcium plays an important role in uterine muscle contraction and blood clotting. Previous studies have suggested that calcium administration may help reduce blood loss after childbirth. However, there is limited evidence regarding its effectiveness during vaginal delivery. The purpose of this study is to evaluate whether administration of intravenous calcium gluconate immediately after umbilical cord clamping can reduce postpartum blood loss following vaginal delivery. Participants will be randomly assigned to receive either calcium gluconate or a placebo solution immediately after umbilical cord clamping during vaginal delivery. Neither the participants nor their healthcare providers will know which treatment was administered. Blood tests routinely obtained during hospitalization after delivery will be used to assess changes in hemoglobin levels and other outcomes related to postpartum bleeding. The results of this study may help determine whether calcium gluconate is a safe and effective intervention for reducing postpartum blood loss after vaginal delivery.

Key facts

Study ID

NCT07714902

Run by

Rambam Health Care Campus

People needed

710

Starts

2026-06-24

Expected to finish

2027-12-01

Last updated by the study team

2026-07-20

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Gestational age of 37 weeks or more, and planning a vaginal delivery.

You may not qualify if…

• Age younger than 18 years old.
• Patients treated with calcium channel blockers
• Patients with Preeclampsia with severe features receiving magnesium sulfate infusion.
• Chronic renal failure and hyperphosphatemia
• Patients with known Para-Thyroid disease
• Sarcoidosis

Where it is running

• Rambam Medical Center — Haifa, Israel (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.